secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-12-03T23:59:59+00:00
Accession:  0001193125-24-269400
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics completes enrollment of 135 patients in Phase 2 AMPLIFY-7P study for ELI-002
--------------------------------------------------------------------------------

- Phase 2 study ELI-002 7P enrolled 135 mKRAS-driven PDAC patients post-surgery, randomized 2:1 vs observation.
- Interim analysis of disease-free survival (DFS) expected in H1 2025, with possible final analysis in H2 2025.
- Enrollment pace exceeded expectations; patients eligible cross-over to ELI-002 upon progression.
- Primary endpoint is DFS; key secondary endpoints include overall survival and vaccine immunogenicity.
- Previous Phase 1a data showed favorable safety and T-cell responses; SITC 2024 data presented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000119312524269400/0001193125-24-269400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000119312524269400/d858884d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-269400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer